

**Table S1.** Baseline characteristics of patients receiving rosuvastatin vs. atorvastatin in the AUMC cohort

|                                                                 | Before PSM adjustment     |                           |           | After PSM adjustment      |                           |           |
|-----------------------------------------------------------------|---------------------------|---------------------------|-----------|---------------------------|---------------------------|-----------|
|                                                                 | Rosuvastatin<br>(n=2,532) | Atorvastatin<br>(n=5,282) | Std. diff | Rosuvastatin<br>(n=2,187) | Atorvastatin<br>(n=4,808) | Std. diff |
| Age group                                                       |                           |                           |           |                           |                           |           |
| 18-19                                                           | -0.001                    | 0.001                     | -0.015    | -0.001                    | 0.001                     | -0.015    |
| 20-24                                                           | 0.003                     | 0.004                     | -0.004    | 0.004                     | 0.003                     | 0.005     |
| 25-29                                                           | 0.008                     | 0.006                     | 0.022     | 0.009                     | 0.006                     | 0.027     |
| 30-34                                                           | 0.018                     | 0.013                     | 0.043     | 0.019                     | 0.018                     | 0.009     |
| 35-39                                                           | 0.026                     | 0.027                     | -0.002    | 0.027                     | 0.026                     | 0.005     |
| 40-44                                                           | 0.050                     | 0.058                     | -0.034    | 0.052                     | 0.051                     | 0.002     |
| 45-49                                                           | 0.093                     | 0.082                     | 0.037     | 0.094                     | 0.094                     | 0.001     |
| 50-54                                                           | 0.126                     | 0.128                     | -0.005    | 0.129                     | 0.132                     | -0.008    |
| 55-59                                                           | 0.143                     | 0.133                     | 0.029     | 0.142                     | 0.144                     | -0.005    |
| 60-64                                                           | 0.146                     | 0.141                     | 0.015     | 0.146                     | 0.142                     | 0.012     |
| 65-69                                                           | 0.123                     | 0.132                     | -0.029    | 0.123                     | 0.123                     | -0.001    |
| 70-74                                                           | 0.120                     | 0.125                     | -0.016    | 0.119                     | 0.119                     | 0.001     |
| 75-79                                                           | 0.079                     | 0.083                     | -0.015    | 0.076                     | 0.078                     | -0.008    |
| 80-84                                                           | 0.045                     | 0.050                     | -0.022    | 0.043                     | 0.047                     | -0.018    |
| 85-89                                                           | 0.016                     | 0.015                     | 0.007     | 0.014                     | 0.014                     | 0.005     |
| 90-94                                                           | 0.002                     | 0.003                     | -0.013    | 0.002                     | 0.002                     | -0.004    |
| Female                                                          | 0.455                     | 0.482                     | -0.053    | 0.457                     | 0.452                     | 0.010     |
| Disease                                                         |                           |                           |           |                           |                           |           |
| Essential hypertension                                          | 0.460                     | 0.452                     | 0.016     | 0.454                     | 0.448                     | 0.013     |
| Obesity                                                         | 0.013                     | 0.011                     | 0.020     | 0.012                     | 0.011                     | 0.016     |
| CCI score                                                       | 2.673                     | 2.811                     | -0.060    | 2.679                     | 2.666                     | 0.006     |
| DCSI                                                            | 0.398                     | 0.394                     | 0.005     | 0.385                     | 0.397                     | -0.015    |
| CHA2DS2VASc                                                     | 2.450                     | 2.510                     | -0.049    | 2.438                     | 2.424                     | 0.011     |
| Atherosclerosis of arteries of the extremities                  | 0.006                     | 0.005                     | 0.005     | 0.006                     | 0.005                     | 0.01      |
| Peripheral arterial occlusive disease                           | 0.018                     | 0.014                     | 0.031     | 0.018                     | 0.016                     | 0.012     |
| Peripheral circulatory disorder due to type 2 diabetes mellitus | 0.041                     | 0.035                     | 0.03      | 0.041                     | 0.041                     | -0.001    |
| Peripheral vascular complication                                | 0.045                     | 0.037                     | 0.039     | 0.045                     | 0.044                     | 0.004     |
| Peripheral vascular disease                                     | 0.062                     | 0.055                     | 0.028     | 0.061                     | 0.064                     | -0.01     |
| Medication*                                                     |                           |                           |           |                           |                           |           |
| Anti-diabetic drugs                                             | -0.001                    | 0.002                     | -0.043    | -0.001                    | 0.002                     | -0.045    |
| ACEI                                                            | 0.002                     | 0.004                     | -0.035    | 0.002                     | 0.004                     | -0.044    |
| ARBs                                                            | 0.072                     | 0.097                     | -0.087    | 0.073                     | 0.069                     | 0.019     |
| Beta-blockers                                                   | -0.001                    | 0.003                     | -0.041    | -0.001                    | 0.003                     | -0.035    |
| Calcium channel blockers                                        | 0.004                     | 0.002                     | 0.026     | 0.004                     | 0.002                     | 0.026     |
| Thiazide diuretics                                              | 0.010                     | 0.007                     | 0.031     | 0.009                     | 0.008                     | 0.019     |
| Other diuretics                                                 | 0.002                     | 0.001                     | 0.022     | 0.002                     | -0.001                    | 0.035     |

|                          |       |       |        |       |       |        |
|--------------------------|-------|-------|--------|-------|-------|--------|
| Nitrates                 | 0.011 | 0.011 | 0.001  | 0.009 | 0.011 | -0.019 |
| Aspirin                  | 0.287 | 0.250 | 0.083  | 0.272 | 0.282 | -0.022 |
| Other antiplatelet drugs | 0.009 | 0.005 | 0.047  | 0.008 | 0.007 | 0.001  |
| Warfarin                 | 0.013 | 0.010 | 0.027  | 0.013 | 0.011 | 0.019  |
| Digoxin                  | 0.008 | 0.007 | 0.015  | 0.008 | 0.007 | 0.008  |
| NSAIDs                   | 0.007 | 0.010 | -0.039 | 0.006 | 0.008 | -0.021 |

---

\*Drugs were grouped by class, and within each class, only the drug with the highest standardized difference after PSM was selected to represent the group.

PSM, propensity score matching; CCI, Charlson Comorbidity Index; DCSI, Diabetes Complications Severity Index; Std. diff., standardized difference; ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; NSAIDs, nonsteroidal anti-inflammatory drugs.